In summary, ACTN1 participated in the tumorigenesis and EMT of GC via the AKT/GSK3β/β-Catenin pathway and was correlated to poor prognosis, and could be a promising candidate for GC treatment. The gene discussed is AKT1; the disease is gastric cancer.